Malapelle, Umberto http://orcid.org/0000-0003-3211-9957
Leighl, Natasha http://orcid.org/0000-0002-3249-4602
Addeo, Alfredo
Hershkovitz, Dov http://orcid.org/0000-0002-7954-4486
Hochmair, Maximilian J.
Khorshid, Ola
Länger, Florian
de Marinis, Filippo
Peled, Nir
Sheffield, Brandon S.
Smit, Egbert F.
Viteri, Santiago
Wolf, Jürgen
Venturini, Filippo
O’Hara Jr, Richard M.
Rolfo, Christian http://orcid.org/0000-0002-7860-8417
Article History
Received: 4 January 2024
Revised: 25 April 2024
Accepted: 30 April 2024
First Online: 15 May 2024
Competing interests
: Umberto Malapelle: Personal fees (consultant and/or speaker bureau): Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GSK, AstraZeneca, Janssen, Diatech, Novartis, and Hedera. Alfredo Addeo: Consulting or advisory role: Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Roche, MSD, Pfizer, Eli Lilly, Astellas, Takeda, and Amgen; speaker’s bureau: Eli Lilly, and AstraZeneca. Florian Länger: Consulting or advisory role: AstraZeneca, Bayer Vital GmbH, Boehringer Ingelheim, Bristol Myers Squibb, Hoffmann-La Roche, Lilly, MSD, speaker’s bureau: AstraZeneca, Bayer Vital GmbH, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Hoffmann-La Roche, Janssen-Cilag, Lilly, MSD, and Takeda. Egbert F. Smit: Advisory/consultancy (institution): Lilly, AstraZeneca, Boehringer Ingelheim, Roche/Genentech, Bristol Myers Squibb, Merck, MSD, Takeda, Bayer, Regeneron, Novartis, Daiichi Sankyo, Seattle Genetics; research funding (institution): Boehringer Ingelheim, Bayer, Roche/Genentech, AstraZeneca, and Bristol Myers Squibb. Ola Khorshid: Advisory & speaker for: MSD, AstraZeneca, Lilly, Pfizer, Boehringer Ingelheim, Hikma, and Novartis. Dov Hershkovitz: Advisor, honoraria, and research funding (institution): Lilly, AstraZeneca, MSD, Roche/Genentech, Bristol Myers Squibb, Takeda, Sanofi, Novartis, Biond Biologics, and ImageneAI. Maximilian J. Hochmair: Personal fees and nonfinancial support: AstraZeneca, Boehringer Ingelheim, Takeda, Roche; personal fees: MSD, Lilly, and BMS. Natasha Leighl: Institutional research funding: Amgen, Array, AstraZeneca, Bayer, BMS, Eli Lilly, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Guardant Health, Inivata, MSD, Novartis, Pfizer, Roche, Takeda; honoraria (independent CME lectures): Amgen, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, GSK, MSD, Novartis, Puma Biotechnology, Sanofi Genzyme, and Takeda. Filippo de Marinis: Personal advisory fees: AstraZeneca, Bristol Myers Squibb, Novartis, F. Hoffman La-Roche Ltd., and MSD. Nir Peled: Advisor, honoraria, and research funding: Bristol Myers Squibb, Eli Lilly, Foundation Medicine, Guardant Health, Merck Serono Ltd., Herzliya, Israel, an affiliate of Merck KGaA, MSD, Novartis, NovellusDx, Pfizer, Roche, and Takeda. Brandon S. Sheffield: Advisory board meetings: Amgen, AstraZeneca, Bayer, Eli Lilly, Janssen, MSD, Novartis, Pfizer, and Roche; has received honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, MSD, Novartis, Pfizer, Roche, and Thermo Fisher; grant support: AstraZeneca, Biocartis, Boehringer Ingelheim, Eli Lilly, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Novartis, Pfizer, Roche, and Thermo Fisher; research funding: AstraZeneca, Biocartis, Boehringer Ingelheim, Eli Lilly, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Novartis, Pfizer, Roche, and ThermoFisher. Santiago Viteri: Consulting or advisory role: AbbVie, Bristol Myers Squibb, Roche, Takeda, AstraZeneca, MSD; speaker’s bureau fees: Bristol Myers Squibb, MSD, Roche, AstraZeneca; travel expenses: Roche, OSE Pharma, BMS, MSD, Merck, Puma Biotechnology, and Janssen Cilag. Jürgen Wolf: Consulting or advisory role: Amgen, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharma, Daiichi Sankyo, Ignyta, Janssen, Eli Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda; research funding (institution): Bristol Myers Squibb, Janssen, Novartis, and Pfizer; travel, accommodations, expenses: Amgen, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharma, Daiichi Sankyo, Ignyta, Janssen, Eli Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Seattle Genetics, and Takeda. Filippo Venturini: Employee of Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA. Richard O’Hara: Employee of EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA. Christian Rolfo: speaker honoraria: AstraZeneca, Roche and MSD; advisory board honoraria: Inivata, Archer, Boston Pharmaceuticals, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Novartis, Bayer, Invitae, Regeneron, Janssen, Bostongene, Novocure; scientific advisory board member: Imagene; institutional research funding: LCRF- Pfizer and NCRF; non-renumerated research support: Guardant Health and Foundation Medicine; non-renumerated leadership roles: the International Society of Liquid Biopsy (ISLB), the International Association for Study of Lung Cancer (IASLC), and the European School of Oncology (ESO).